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Myospherulosis: An Iatrogenic Complication of
Antisyphilitic 1i'eatment?
COLLEAGUES- A 42-y-old Swiss male gardener was referred to the
dermatology outpatient clinic in July 1988 with a history of two
painful masses located symmetrically in the buttocks. The right
mass had been partly excised at another institution a few weeks
previously and was described as a whitish nodule. Histologic ex-
amination revealed a cystic structure filled with rounded bodies
containing small spheres, compatible with coccidioidomycosis.
In view of the patient's origin, the fact that he had not traveled
abroad, and his excellent physical condition, the diagnosis was
reconsidered. Serology for coccidioidomycosis was negative, as
were all cultures from the tissue specimen including that on
Sabouraud's medium.
Further interrogation revealed a history of syphilis in 1974. The
dermatology outpatient clinic files showed that at that time the
patient had been treated for meningovascular syphilis with a 21-d
course of intramuscular procaine penicillin.
Physical examination was unremarkable except for a firm, ten-
der 4 x 2-cm nodule located deep in the left buttock. The over-
lying skin was unremarkable. There was no evidence of recur-
rence on the right buttock and the excision scar was normal. The
erythrocyte sedimentation rate and leukocyte count were normal
and serology for human immunodeficiency virus and venereal
disease research laboratory test were negative. No abnormalities
were observed on chest radiographs.
Tissue blocks were obtained from the other institution; sec-
tions were cut and stained with hematoxylin and eosin, van Gie-
son-Elastin, periodic acid-Schiff, Giemsa, Masson's trichrome,
Pearl's stain, Grocott, and Lepehne benzioline for hemoglobin.
The thick outer fibrohyalin capsule contained granulation tissue
in places with occasional foreign body giant cells and groups of
foam cells near cholesterol crystals in certain areas. The cavity
contained a fine granular material in which were numerous thin-
walled spherules of various sizes. Most of these contained 2-20
smaller spherules (4-6 J.lm). The histologic picture and staining
characteristics were consistent with myospherulosis (figure I).
The first description, by McClatchie et al. [1] in 1969, of myo-
spherulosis in Africa concerned cases found in subcutaneous tis-
sue. In 1977 in the USA, Kyriakos [2] described 16 cases, all iden-
tified as ear, nose, and throat (ENT) pathology. Only 6 cases have
been documented in Europe, all in France. Of the 67 cases de-
scribed worldwide, 36 had an ENT localization, 28 were in pe-
ripheral soft tissues, and 3 in unusual locations: breast, ovary,
and central nervous system. Only one documented case involv-
ing subcutaneous tissues has been clearly linked to an antisyphi-
litic treatment consisting of intramuscular injections of benzathine
penicillin [3]. In the present case, the first to our knowledge to
be reported from Switzerland, we think the development of
myospherulosis can be directly linked to the intramuscular injec-
tions of procaine penicillin administered 14 y earlier.
Theories regarding the pathogenesis of myospherulosis have
evolved from early hypotheses implicating fungi, algae, and pollens
to current points of view that the lesions are iatrogenic. Experimen-
tally it has been shown that contact between oil-based substances
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Figure 1. Sac containing numerous spherules 4-6 J.lm in diameter
(hematoxylin-eosin stain; x 560).
and red blood cells can produce a lesion typical of myospherulo-
sis. The substances may be exogenous, such as hemostatic gauze
impregnated with petrolatum or antibiotics, as seen in the ENT
cases, or oily preparations of injectable drugs as seen in the sub-
cutaneous cases. Endogenous substances such as debris of trau-
matic or necrotic origin have also been implicated in the patho-
genesis. The coating of erythrocytes by lipids produces the typical
spherules ("bag of marbles") seen on histologic examination [4-6].
The incidence of myospherulosis is probably greatly underes-
timated considering the wide use of intramuscular injections, in
particular of antibiotics. In the present case, the long delay be-
fore the appearance of symptoms, the unspecific character of the
lesions, and the difficulty in identifying the unusual histologic
lesion all delayed the correct diagnosis. This case reminds us that
myospherulosis must be included in the differential diagnosis of
subcutaneous nodules of undetermined origin to prevent patients
from undergoing unnecessary investigations and treatment.
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Registry on Mucormycosis in Dialysis Patients
COLLEAGUES - Sane et at. [1] reported a patient with myelofibro-
sis and transfusional iron overload, treated with deferoxamine,
who died from disseminated mucormycosis caused by Rhizopus
oryzae. An analogous case was reported recently [2], and deferox-
amine therapy is proposed to be the risk factor for this zygomy-
cete infection.
Sane et at. [1] noted that mucormycosis has been reported in
hemodialysis patients worldwide. As of 1 February 1989, 25 cases
had been reported among nondiabetic dialysis patients [3-9], and
we are aware of several more unpublished cases.
Several authors have linked this infectious complication to the
use of deferoxamine. Of the 25 reported dialysis patients, 22 were
receiving deferoxamine for the treatment ofeither aluminum over-
load (18 cases) or iron overload (4 cases). The infection was fatal
in 22 (88070) of 25 patients. In most instances, the diagnosis was
made postmortem. When the fungus was cultured, it was always
genus Rhizopus. The mechanism underlying this fulminant in-
fection in dialysis patients treated with deferoxamine is unknown.
To identify predisposing factors, we are establishing a registry
of dialysis patients who have developed mucormycosis. Thus, we
request physicians who have observed this mycosis in dialysis pa-
tients to contact us. We will respond with a detailed question-
naire in the hope of identifying risk factors for this infection.
(To respond, see footnotes.)
To report patients to the registry, questionnaires may be obtained from
the following: Dr. Johan Boelaert, Algemeen Ziekenhuis St Jan, B-8000
Brugge, Belgium; Dr. Andrew Fenves, Baylor University Medical Center,
3550 Gaston Ave., Dallas, TX 75246; and Dr. Jack Coburn, Nephrology
Section (WlllL), West Los Angeles V.A. Medical Center, Los Angeles,
CA 90073.
Reprints are available 'from Dr. Boelaert at the address shown above.
JORAN R. BOELAERT, ANDREW Z. FENVES, JACK W. COBURN
Algemeen Ziekenhuis St Jan, Brugge, Belgium; Baylor
University Medical Center, Houston, Texas; West Los
Angeles (California) Veterans Administration Hospital
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